These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34225657)

  • 1. Epidemiology of SARS-CoV2 in Qatar's primary care population aged 10 years and above.
    Syed MA; Al Nuaimi AS; A/Qotba HA; Nasrallah GK; Althani AA; Yassine HM; Zainel AA; Khudadad H; Marji T; Veettil ST; Al-Jighefee HT; Younes S; Shurrab F; Al-Sadeq DW; AlFehaidi AAS; Yfakhroo AI; AlMesaifri MA; Al Mujalli H; Al Abdulla SA; Al Kuwari MG; Azad FM; Al Malki BAM; Abdulmalik MA
    BMC Infect Dis; 2021 Jul; 21(1):645. PubMed ID: 34225657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Response to SARS-CoV-2: A Cohort Study in Qatar's Primary Care Settings.
    Syed MA; A/Qotba HA; Al Nuaimi AS; Nasrallah GK; Althani AAJF; Zainel AA; Khudadad H; Marji T; Veettil ST; AlFehaidi AS; Yfakhroo AI; AlMesaifri MA; Al-Baghdadi TT; Al Mujalli H; Al Abdulla SA; Abdulmalik MA
    J Prim Care Community Health; 2021; 12():21501327211050569. PubMed ID: 34663129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating point prevalence of COVID-19 in Qatar's primary care registered population: an RT-PCR drive-through study protocol.
    Syed MA; Al Nuaimi AS; A/Qotba HA; Al Mujjali H; Abdulmalik MA; Al Abdulla SA; Aladab AH; Kutty KG; Hamed ES
    BJGP Open; 2021 Apr; 5(2):. PubMed ID: 33318046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 Surveillance in the Primary Health Care Population of Qatar: Experience of Prioritizing Timeliness Over Representativeness When Sampling the Population.
    A/Qotba HA; Al Nuaimi AS; Al Mujalli H; Zainel AA; Khudadad H; Marji T; Veettil ST; Syed MA
    Front Public Health; 2021; 9():654734. PubMed ID: 34026715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar.
    Seedat S; Chemaitelly H; Ayoub HH; Makhoul M; Mumtaz GR; Al Kanaani Z; Al Khal A; Al Kuwari E; Butt AA; Coyle P; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Yassine HM; Al Kuwari MG; Al Romaihi HE; Al-Thani MH; Bertollini R; Abu-Raddad LJ
    Sci Rep; 2021 Sep; 11(1):18182. PubMed ID: 34521903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J; Sharma P; Berhane S; van Wyk SS; Nyaaba N; Domen J; Taylor M; Cunningham J; Davenport C; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Van den Bruel A; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD013705. PubMed ID: 35866452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J; Deeks JJ; Berhane S; Taylor M; Adriano A; Davenport C; Dittrich S; Emperador D; Takwoingi Y; Cunningham J; Beese S; Domen J; Dretzke J; Ferrante di Ruffano L; Harris IM; Price MJ; Taylor-Phillips S; Hooft L; Leeflang MM; McInnes MD; Spijker R; Van den Bruel A;
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013705. PubMed ID: 33760236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample - Indiana, April 25-29, 2020.
    Menachemi N; Yiannoutsos CT; Dixon BE; Duszynski TJ; Fadel WF; Wools-Kaloustian KK; Unruh Needleman N; Box K; Caine V; Norwood C; Weaver L; Halverson PK
    MMWR Morb Mortal Wkly Rep; 2020 Jul; 69(29):960-964. PubMed ID: 32701938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey.
    Pouwels KB; House T; Pritchard E; Robotham JV; Birrell PJ; Gelman A; Vihta KD; Bowers N; Boreham I; Thomas H; Lewis J; Bell I; Bell JI; Newton JN; Farrar J; Diamond I; Benton P; Walker AS;
    Lancet Public Health; 2021 Jan; 6(1):e30-e38. PubMed ID: 33308423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Oct; 22(1):694. PubMed ID: 34635140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; Al Kanaani Z; Al Khal A; Al Kuwari E; Butt AA; Coyle P; Jeremijenko A; Kaleeckal AH; Latif AN; Owen RC; Rahim HFA; Al Abdulla SA; Al Kuwari MG; Kandy MC; Saeb H; Ahmed SNN; Al Romaihi HE; Bansal D; Dalton L; Al-Thani MH; Bertollini R
    Sci Rep; 2021 Mar; 11(1):6233. PubMed ID: 33737535
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.